Accéder au contenu
Merck
Toutes les photos(1)

Documents

SML1026

Sigma-Aldrich

Lasofoxifene tartrate

≥98% (HPLC)

Synonyme(s) :

(-)-cis-6-Phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol tartrate, (5R,6S)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol tartrate, CP-336,156 tartrate

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C28H31NO2 · C4H6O6
Numéro CAS:
Poids moléculaire :
563.64
Code UNSPSC :
51111800
ID de substance PubChem :
Nomenclature NACRES :
NA.77

Pureté

≥98% (HPLC)

Forme

powder

Conditions de stockage

desiccated

Couleur

white to beige

Solubilité

DMSO: 10 mg/mL, clear

Température de stockage

2-8°C

Chaîne SMILES 

OC1=CC=C(C(CC[C@@H]2C3=CC=CC=C3)=C1)[C@H]2C4=CC=C(OCCN5CCCC5)C=C4.O=C(O)[C@@H](O)[C@H](O)C(O)=O

InChI

1S/C28H31NO2.C4H6O6/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29;5-1(3(7)8)2(6)4(9)10/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2;1-2,5-6H,(H,7,8)(H,9,10)/t26-,28+;1-,2-/m10/s1

Clé InChI

INEHJXCWEVNEDZ-LUDNRVPPSA-N

Actions biochimiques/physiologiques

Lasofoxifene is a third-generation selective estrogen receptor modulator (SERM).
Lasofoxifene possesses strong resistance to intestinal wall glucuronidation and thus promotes oral bioavailability. In postmenopausal women, it reduces bone resorption, bone loss and low density lipoprotein (LDL) cholesterol. Selective and regular dose of Lasofoxifene is known to reduce the risk of fractures, breast cancer, major coronary heart disease, and stroke.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Lasofoxifene in postmenopausal women with osteoporosis.
Cummings S R, et al.
The New England Journal of Medicine, 362(8), 686-696 (2010)
Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis.
Gennari L, et al.
Expert Opinion on Investigational Drugs, 15(9), 1091-1103 (2006)
Nam Sook Kim et al.
Journal of separation science, 43(14), 2750-2765 (2020-04-17)
An analytical method for the simultaneous and reliable determination of 20 antigout and antiosteoporosis pharmaceutical compounds in adulterated health food products was developed using liquid chromatography with electrospray ionization tandem mass spectrometry and liquid chromatography with quadrupole-time-of-flight mass spectrometry. The
Kaitlyn J Andreano et al.
Breast cancer research and treatment, 180(3), 635-646 (2020-03-05)
The combination of targeting the CDK4/6 and estrogen receptor (ER) signaling pathways with palbociclib and fulvestrant is a proven therapeutic strategy for the treatment of ER-positive breast cancer. However, the poor physicochemical properties of fulvestrant require monthly intramuscular injections to
Nam Sook Kim et al.
Journal of pharmaceutical and biomedical analysis, 179, 113003-113003 (2019-12-10)
The aim of this study was to simultaneously determine the presence of unauthorized drug substances in health foods and herbal products used in the treatment of conditions such as gout and anti-osteoporosis. Therefore, we developed and optimised a rapid and

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique